title: Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
authors.forename: R
authors.initials: R
authors.lastname: Calne
authors.forename: P
authors.initials: P
authors.lastname: Friend
authors.forename: S
authors.initials: S
authors.lastname: Moffatt
authors.forename: A
authors.initials: A
authors.lastname: Bradley
authors.forename: G
authors.initials: G
authors.lastname: Hale
authors.forename: J
authors.initials: J
authors.lastname: Firth
authors.forename: J
authors.initials: J
authors.lastname: Bradley
authors.forename: K
authors.initials: K
authors.lastname: Smith
authors.forename: H
authors.initials: H
authors.lastname: Waldmann
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000494:pharmacology / Q000627:therapeutic use*; D002102:Cadaver; D016572:Cyclosporine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D016572:Cyclosporine